NCT00909077 - The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

June 1, 2012

Study Completion Date

August 1, 2017

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG

Dexamethasone

Dexamethasone tablets: 40 mg/day for four days

DRUG

Dexamethasone and Rituximab

Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)

Trial Locations (10)

DK-9000

Aalborg Hospital, Aalborg

DK-2100

Copenhagen University Hospital Rigshospitalet, Copenhagen

DK-6700

Esbjerg Hospital, Esbjerg

DK-2730

Copenhagen University Hospital Herlev, Department of Haematology, Herlev

DK-7500

Regional Hospital Holstebro, Holstebro

DK-4700

Naestved Hospital, Næstved

DK-5000

Odense University Hospital, Odense

DK-4000

Roskilde Hospital, Roskilde

DK-7100

Vejle Hospital, Vejle

DK-8800

Viborg Hospital, Viborg

All Listed Sponsors

lead

Copenhagen University Hospital at Herlev

OTHER